Table 1 Women’s and tumoral characteristics according to readmission

Total

76 (7.2)

87 (8.2)

71 (6.7)

821 (77.8)

 50–54

24 (31.6)

22 (25.3)

32 (45.1)^a

224 (27.3)^a

 55–59

25 (32.9)

27 (31.0)

16 (22.5)

212 (25.8)

 60–64

21 (27.6)

19 (21.8)

17 (23.9)

225 (27.4)

 65–69

6 (7.9)

19 (21.8)

6 (8.5)

160 (19.5)

 Missing

0

0

0

0

 0

61 (80.3)

61 (70.1)

47 (66.2)

603 (73.4)

 1

15 (19.7)

26 (29.9)

24 (33.8)

218 (26.6)

 Missing

0

0

0

0

 Screen-detected

50 (65.8)

62 (71.3)

42 (59.2)

568 (69.2)

 Interval Cancer

26 (34.2)

25 (28.7)

29 (40.8)

253 (30.8)

 Missing

0

0

0

0

 In situ

6 (8.1)

8 (9.6)

5 (7.4)

84 (10.4)

 Stage I

36 (48.6)^a

38 (45.8)

18 (26.5)^a,b

368 (45.5)^b

 Stage II

25 (33.8)

26 (31.3)

28 (41.2)

249 (30.8)

 Stage III/IV

7 (9.5)

11 (13.3)

17 (25.0)^a

108 (13.3)^a

 Missing

2

4

3

9

 Unifocal

43 (70.5)^a

54 (75.0)

49 (81.7)

594 (85.3)^a

 Multifocal and/or multicentric

18 (29.5)^a

18 (25.0)

11 (18.3)

102 (14.7)^a

 Missing

15

15

11

125

 Well differentiated

13 (21.0)

18 (27.3)^a

4 (7.0)^a,b

193 (29.2)^b

 Moderately differentiated

33 (53.2)

34 (51.5)

27 (47.4)

248 (37.6)

 Poorly differentiated/ undifferentiated

16 (25.8)

14 (21.2)^a

26 (45.6)^a

219 (33.2)

 Not applicable

7

4

1

49

 Missing

7

17

13

112

 Luminal A

29 (58.0)

35 (64.8)

19 (41.3)

324 (51.8)

 Luminal B

13 (26.0)

9 (16.7)

10 (21.7)

181 (28.9)

 HER2

3 (6.0)

3 (5.6)

11 (23.9)^a

51 (8.1)^a

 Triple-negative

5 (10.0)

7 (13.0)

6 (13.0)

70 (11.2)

 Missing

26

37

25

195